Perrigo Company plc (PRGO)
- Previous Close
26.80 - Open
26.83 - Bid 26.89 x 800
- Ask 26.91 x 900
- Day's Range
26.76 - 27.19 - 52 Week Range
23.14 - 31.17 - Volume
1,251,609 - Avg. Volume
1,761,651 - Market Cap (intraday)
3.706B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-1.20 - Earnings Date Aug 4, 2025 - Aug 18, 2025
- Forward Dividend & Yield 1.16 (4.29%)
- Ex-Dividend Date May 30, 2025
- 1y Target Est
34.60
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
www.perrigo.com8,379
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PRGO
View More
Performance Overview: PRGO
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRGO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRGO
View MoreValuation Measures
Market Cap
3.71B
Enterprise Value
6.92B
Trailing P/E
--
Forward P/E
8.91
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.86
Price/Book (mrq)
0.85
Enterprise Value/Revenue
1.60
Enterprise Value/EBITDA
12.96
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.16%
Return on Assets (ttm)
2.93%
Return on Equity (ttm)
-3.64%
Revenue (ttm)
4.34B
Net Income Avi to Common (ttm)
-164.7M
Diluted EPS (ttm)
-1.20
Balance Sheet and Cash Flow
Total Cash (mrq)
409.9M
Total Debt/Equity (mrq)
87.89%
Levered Free Cash Flow (ttm)
379.52M
Research Analysis: PRGO
View MoreResearch Reports: PRGO
View MorePerrigo Earnings: Margin Strength and Infant Formula Recovery Drive Solid Q1 Performance
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
RatingPrice TargetLooking for a better entry point
Perrigo, founded in 1887, is a leading manufacturer of generic over-the-counter healthcare products and supplier of infant formulas for the store-brand market. Perrigo's private-label consumer products encompass a variety of cold/allergy, gastrointestinal, first aid, motion sickness, vitamin, smoking cessation, and other remedies. The company has a market cap of approximately $4 billion after divesting its RX pharmaceutical business in 2021. Headquartered in Dublin, Ireland, Perrigo has over 8,300 employees.
RatingPrice TargetStocks are up at midday. The major indices are all higher by about 1%. Wall
Stocks are up at midday. The major indices are all higher by about 1%. Wall Street is showing relief that President Trump has given a tariff reprieve to certain electronics. Meanwhile, more big banks are warning that tariffs will hurt profit earnings growth. Citigroup and Morgan Stanley lowered their forecasts for the year. The yield on the 10-year Treasury note is 4.41%. Oil is at $62 per barrel. Bitcoin is near $85,000.
Perrigo Earnings: Soft Finish to 2024, but Path to Continued Recovery Remains Intact
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
RatingPrice Target